Nevisense and its underlying electrical impedance spectroscopy (EIS) technology can measure skin barrier integrity and monitor changes to the skin barrier function in atopic dermatitis (AD), a new study suggests.
EIS technology measures how electricity flows through skin at different depths.
The new study, which appears in Allergy, is a collaborative scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland.
In the study, human ex vivo skin samples were exposed to inflammatory cytokines interleukin (IL)-4, IL-13 and IL-22, resembling a similar inflammatory response in skin lesions from patients with AD. SciBase’s Nevisense EIS measurements were highly sensitive to detect this inflammatory disruption of the skin barrier function over time. Pivotal genes that play a role in skin barrier changes and type-2 response have been identified. In addition, genes involved in the restoration of skin inflammation and barrier function by medication with dupilumab (Dupixent, Sanofi & Regeneron) were identified in the study. The study emphasizes the potential of Nevisense to be used in measuring and monitoring skin barrier integrity during different disease states of atopic dermatitis, including treatment monitoring.
“We are very encouraged to see that EIS measurements could determine skin barrier integrity and monitor changes to the skin barrier function during type 2 and non-type 2 skin inflammation in an atopic dermatitis model. EIS provides an increasingly useful tool for the better understanding of molecular mechanisms of skin barrier integrity,” says Professor Cezmi Akdis of the SIAF, in a news release.
